{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T16:22:20Z","timestamp":1783786940266,"version":"3.55.0"},"reference-count":21,"publisher":"Wiley","issue":"24","license":[{"start":{"date-parts":[[2017,6,17]],"date-time":"2017-06-17T00:00:00Z","timestamp":1497657600000},"content-version":"vor","delay-in-days":16,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Veterinary Record"],"published-print":{"date-parts":[[2017,6]]},"abstract":"<jats:p>\n                    A monitoring programme of marbofloxacin susceptibility of bacteria from Europe causing respiratory tract infection and meningitis in pigs has been active since 1994 and 2002, respectively. Monitoring digestive, metritis and urinary tract infection (UTI) in pigs has been active since 2005 and susceptibility results until 2013 are presented. Minimum inhibitory concentration (MIC) was determined by broth microdilution. For MIC interpretation, V\u00e9toquinol\u2010evaluated breakpoints were applied. For digestive pathogens,\n                    <jats:italic>Escherichia coli<\/jats:italic>\n                    and\n                    <jats:italic>Salmonella<\/jats:italic>\n                    species (1717 and 300 isolates, respectively) exhibited 7.5 per cent resistance in\n                    <jats:italic>E coli<\/jats:italic>\n                    and no resistance in\n                    <jats:italic>Salmonella<\/jats:italic>\n                    species. Similarly,\n                    <jats:italic>E coli<\/jats:italic>\n                    from metritis (369 isolates) had 7.0 per cent resistance to marbofloxacin. However,\n                    <jats:italic>E coli<\/jats:italic>\n                    from UTI (633 isolates) had higher resistance (10.4 per cent). For\n                    <jats:italic>Streptococcus suis<\/jats:italic>\n                    causing meningitis (585 isolates), marbofloxacin susceptibility was very high with only 0.5 per cent resistance and 0.4 per cent resistance was observed with\n                    <jats:italic>S suis<\/jats:italic>\n                    causing respiratory disease (729 isolates). Other respiratory pathogens were also highly susceptible to marbofloxacin with no resistance in\n                    <jats:italic>Actinobacillus pleuropneumoniae<\/jats:italic>\n                    (647 isolates) or\n                    <jats:italic>Bordetella bronchiseptica<\/jats:italic>\n                    (504 isolates), 0.1 per cent resistance in\n                    <jats:italic>Pasteurella multocida<\/jats:italic>\n                    (1373 isolates) and 1.4 per cent resistance in\n                    <jats:italic>Haemophilus parasuis<\/jats:italic>\n                    (145 isolates). There was no apparent change in marbofloxacin MIC over time for any bacterial pathogen based on MIC\n                    <jats:sub>50\/90<\/jats:sub>\n                    . These data confirm previously published MIC results from porcine and other animal infections.\n                  <\/jats:p>","DOI":"10.1136\/vr.103954","type":"journal-article","created":{"date-parts":[[2017,3,27]],"date-time":"2017-03-27T20:56:41Z","timestamp":1490648201000},"page":"591-591","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":16,"title":["Survey of susceptibility to marbofloxacin in bacteria isolated from diseased pigs in Europe"],"prefix":"10.1002","volume":"180","author":[{"given":"F.","family":"El Garch","sequence":"first","affiliation":[{"name":"V\u00e9toquinol S.A., Global Drug Development 34 rue du Ch\u00eane Sainte Anne Lure 70200 France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Kroemer","sequence":"additional","affiliation":[{"name":"V\u00e9toquinol S.A., Global Drug Development 34 rue du Ch\u00eane Sainte Anne Lure 70200 France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Galland","sequence":"additional","affiliation":[{"name":"V\u00e9toquinol S.A., Global Drug Development 34 rue du Ch\u00eane Sainte Anne Lure 70200 France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Morrissey","sequence":"additional","affiliation":[{"name":"IHMA Europe S\u00e0rl Rte de l'Ile\u2010au\u2010Bois 1A, Monthey\/VS 1870 Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Woehrle","sequence":"additional","affiliation":[{"name":"V\u00e9toquinol S.A., Global Drug Development 34 rue du Ch\u00eane Sainte Anne Lure 70200 France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2017,6,17]]},"reference":[{"key":"e_1_2_6_2_1","unstructured":"CA\u2010SFM(2013).Antibiogramme V\u00e9t\u00e9rinaire du Comit\u00e9 de l'antibiogramme de la soci\u00e9t\u00e9 fran\u00e7aise de microbiologie.www.sfm\u2010microbiologie.org"},{"key":"e_1_2_6_3_1","volume-title":"Performance Standards for Antimicrobial Disk and Dilution Susceptibility Tests for Bacteria Isolated From Animals; Approved Standard","author":"CLSI","year":"2008"},{"key":"e_1_2_6_4_1","volume-title":"Performance Standards for Antimicrobial Disk and Dilution Susceptibility Tests for Bacteria Isolated From Animals; Fourth Edition","author":"CLSI","year":"2013"},{"key":"e_1_2_6_5_1","volume-title":"Performance Standards for Antimicrobial Disk and Dilution Susceptibility Tests for Bacteria Isolated From Animals; Second Informational Supplement","author":"CLSI","year":"2013"},{"key":"e_1_2_6_6_1","unstructured":"CVMP(2007) Public Statement On The Use Of (Fluoro) Quinolones In Food\u2010Producing Animals In The European Union: Development Of Resistance And Impact On Human And Animal Health.www.ema.europa.eu\/docs\/en_GB\/document_library\/Public_statement\/2009\/10\/WC500005152.pdf"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2012.11.004"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vetmic.2014.04.008"},{"key":"e_1_2_6_9_1","unstructured":"ESVAC(2016).Sales of veterinary antimicrobial agents in 29 European countries in 2014.www.ema.europa.eu\/docs\/en_GB\/document_library\/Report\/2016\/10\/WC500214217.pdf"},{"key":"e_1_2_6_10_1","unstructured":"GERMAP(2012).Antimicrobial resistance and consumption. Report on the consumption of antimicrobials and the spread of antimicrobial resistance in human and veterinary medicine in Germany.www.bvl.bund.de\/SharedDocs\/Downloads\/08_PresseInfothek\/Germap_2012_en.html"},{"key":"e_1_2_6_11_1","unstructured":"Guidelines for prudent use of antimicrobials \u2013 Official Journal of the European Union 11.9.2015 (2015\/C299\/04).http:\/\/ec.europa.eu\/health\/antimicrobial_resistance\/docs\/2015_prudent_use_guidelines_en.pdf"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cimid.2013.10.001"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1136\/vr.100246"},{"key":"e_1_2_6_14_1","unstructured":"MARAN(2016) Monitoring of Antimicrobial Resistance and Antibiotic Usage in Animals in the Netherlands in 2015.www.wageningenur.nl\/nl\/Expertises\u2010Dienstverlening\/Onderzoeksinstituten\/Central\u2010Veterinary\u2010Institute\/Publicaties\u2010CVI\/MARAN\u2010Rapporten.htm"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2003.12.011"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2004.09.004"},{"key":"e_1_2_6_17_1","volume-title":"Usage of Antimicrobial Agents and Occurrence of Antimicrobial Resistance in Norway","author":"NORM\/NORM\u2010VET","year":"2013"},{"key":"e_1_2_6_18_1","unstructured":"RESAPATH(2015)French surveillance network for antimicrobial resistance in pathogenic bacteria of animal origin. 2014 Annual Report.www.resapath.anses.fr"},{"key":"e_1_2_6_19_1","unstructured":"SVARM(2015)Swedish veterinary Antimicrobial Resistance Monitoring. 2014 Annual Report.www.sva.se\/en\/antibiotika\/svarm\u2010reports"},{"key":"e_1_2_6_20_1","unstructured":"VARSS(2015). UK Veterinary Antibiotic Resistance and Sales Surveillance 2015.www.gov.uk\/government\/publications\/veterinary\u2010antimicrobial\u2010resistance\u2010and\u2010sales\u2010surveillance\u20102015"},{"key":"e_1_2_6_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/jvp.12134"},{"key":"e_1_2_6_22_1","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.2.4.378"}],"container-title":["Veterinary Record"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1136%2Fvr.103954","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bvajournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1136\/vr.103954","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T10:53:21Z","timestamp":1761562401000},"score":1,"resource":{"primary":{"URL":"https:\/\/bvajournals.onlinelibrary.wiley.com\/doi\/10.1136\/vr.103954"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6]]},"references-count":21,"journal-issue":{"issue":"24","published-print":{"date-parts":[[2017,6]]}},"alternative-id":["10.1136\/vr.103954"],"URL":"https:\/\/doi.org\/10.1136\/vr.103954","archive":["Portico"],"relation":{},"ISSN":["0042-4900","2042-7670"],"issn-type":[{"value":"0042-4900","type":"print"},{"value":"2042-7670","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,6]]}}}